Semaglutide and SLU-PP-332 Interaction

Monitor
Researched 90% confidence

Semaglutide and SLU-PP-332 have an interaction requiring monitoring for interaction with 90% confidence. Combining GLP-1 and ERR agonism may enhance metabolic effects - monitor weight loss rate closely. Both compounds affect the pancreas, so monitoring these systems is recommended.

Compound Profiles

Semaglutide

GLP-1 Receptor Agonist | Weight Loss & Diabetes

Mimics native GLP-1, binding to receptors to stimulate glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite via hypothalamic pathways..

Half-life: ~7 days (168 hours) Typical dose: 0.25mg starting, titrate to 1-2.4mg weekly weight loss, metabolic
glp1 receptor carcinogenic riskinsulin disruptingteratogenic
View full profile

SLU-PP-332

Synthetic Pan-ERR Agonist | Exercise Mimetic & Metabolic Modulator

Binds and activates ERRα/β/γ which regulate energy metabolism gene expression. Upregulates PGC-1α (mitochondrial biogenesis master regulator), activates AMPK pathway, increases mitochondrial density to 1.

Half-life: Under investigation (no human PK data) Typical dose: NO HUMAN DOSE ESTABLISHED (animal studies: 50 mg/kg IP) metabolic, longevity
ampk hepatotoxicinsulin disrupting
View full profile

Combined Organ Load

Pancreas
low
GI Tract
low

Shared Safety Flags

2x 2 compounds affect insulin sensitivity (Semaglutide, SLU-PP-332). Monitor fasting glucose and HbA1c.

Frequently Asked Questions

Can I take Semaglutide with SLU-PP-332?

Yes, but with caution. Combining GLP-1 and ERR agonism may enhance metabolic effects - monitor weight loss rate closely. Regular monitoring is advised.

Is Semaglutide and SLU-PP-332 safe together?

Based on documented research, this combination is considered monitor. However, shared safety flags include: insulin disrupting. Monitor accordingly.

What are the interactions between Semaglutide and SLU-PP-332?

Combining GLP-1 and ERR agonism may enhance metabolic effects - monitor weight loss rate closely. This assessment has 90% confidence and is based on documented research data.

How should I time Semaglutide and SLU-PP-332?

Semaglutide has a half-life of ~7 days (168 hours) and SLU-PP-332 has a half-life of Under investigation (no human PK data). No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: Semaglutide vs SLU-PP-332

This interaction analysis is compiled from research literature and pharmacological mechanism data. Always consult a healthcare professional before combining compounds.